

OPEN

Plasma lipid profiles discriminate bacterial from viral infection in febrile children

Xinzhu Wang¹, Ruud Nijman¹, Stephane Camuzeaux², Caroline Sands¹, Heather Jackson¹, Myrsini Kaforou¹, Marieke Emonts^{3,4,5}, Jethro A. Herberg¹, Ian Maconochie⁶, Enitan D. Carrol^{7,8,9}, Stephane C. Paulus^{8,9}, Werner Zenz¹⁰, Michiel Van der Flier^{11,12}, Ronald de Groot¹², Federico Martinon-Torres^{13,14}, Luregn J. Schlapbach¹⁵, Andrew J. Pollard¹⁶, Colin Fink¹⁷, Taco T. Kuijpers¹⁸, Suzanne Anderson¹⁹, Matthew R. Lewis², Michael Levin¹, Myra McClure^{1*} & EUCLIDS consortium[†]

Fever is the most common reason that children present to Emergency Departments. Clinical signs and symptoms suggestive of bacterial infection are often non-specific, and there is no definitive test for the accurate diagnosis of infection. The 'omics' approaches to identifying biomarkers from the host-response to bacterial infection are promising. In this study, lipidomic analysis was carried out with plasma samples obtained from febrile children with confirmed bacterial infection ($n = 20$) and confirmed viral infection ($n = 20$). We show for the first time that bacterial and viral infection produces distinct profile in the host lipidome. Some species of glycerophosphoinositol, sphingomyelin, lysophosphatidylcholine and cholesterol sulfate were higher in the confirmed virus infected group, while some species of fatty acids, glycerophosphocholine, glycerophosphoserine, lactosylceramide and bilirubin were lower in the confirmed virus infected group when compared with confirmed bacterial infected group. A combination of three lipids achieved an area under the receiver operating characteristic (ROC) curve of 0.911 (95% CI 0.81 to 0.98). This pilot study demonstrates the potential

¹Department of Infectious Disease, Imperial College London, London, W2 1PG, United Kingdom. ²National Phenome Centre and Imperial Clinical Phenotyping Centre, Department of Metabolism, Digestion and Reproduction, IRDB Building, Du Cane Road, Imperial College London, London, W12 0NN, United Kingdom. ³Great North Children's Hospital, Paediatric Immunology, Infectious Diseases & Allergy, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 4LP, United Kingdom. ⁴Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom. ⁵NIHR Newcastle Biomedical Research Centre based at Newcastle upon Tyne Hospitals NHS Trust and Newcastle University, Newcastle upon Tyne, NE4 5PL, United Kingdom. ⁶Department of Paediatric Emergency Medicine, St Mary's Hospital, Imperial College NHS Healthcare Trust, London, W2 1NY, United Kingdom. ⁷Institute of Infection and Global Health, University of Liverpool, Liverpool, L69 7BE, United Kingdom. ⁸Department of Infectious Diseases, Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, United Kingdom. ⁹Liverpool Health Partners, Liverpool, L3 5TF, United Kingdom. ¹⁰Department of General Paediatrics, Medical University of Graz, Graz, Auenbruggerplatz 34/2, 8036, Graz, Austria. ¹¹Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, 3508 AB, The Netherlands. ¹²Pediatric Infectious Diseases and Immunology, Amalia Children's Hospital, and Section Pediatric Infectious Diseases, Laboratory of Medical Immunology, Department of Laboratory Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, 6500 HB, The Netherlands. ¹³Genetic, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago and Universidad de Santiago de Compostela (USC), Galicia, Spain. ¹⁴Translational Pediatrics and Infectious Diseases, Department of Pediatrics, Hospital Clínico Universitario de Santiago de Compostela, Galicia, 15706, Spain. ¹⁵Paediatric Critical Care Research Group, Child Health Research Centre, The University of Queensland and Paediatric Intensive Care Research Group, Queensland Children's Hospital, Brisbane, Australia. ¹⁶Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, OX3 9DU, United Kingdom. ¹⁷Micropathology Ltd, University of Warwick, Warwick, CV4 7EZ, United Kingdom. ¹⁸Division of Pediatric Hematology, Immunology and Infectious diseases, Emma Children's Hospital Academic Medical Center, Amsterdam, 1105 AZ, The Netherlands. ¹⁹Medical Research Council Unit at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia. [†]A comprehensive list of consortium members appears at the end of the paper. *email: m.mcclure@imperial.ac.uk

of metabolic biomarkers to assist clinicians in distinguishing bacterial from viral infection in febrile children, to facilitate effective clinical management and to the limit inappropriate use of antibiotics.

Fever is the one of the most common reasons that children present to Emergency departments in hospitals, especially in children under 5 years of age, in England¹ and in the US². Serious bacterial infection accounts for 5–15% of the febrile children presenting^{3–5} and most cases originating from a viral aetiology are self-limiting. Currently bacterial infection is confirmed by positive microbiological culture of a sterile sample (blood, clean catch urine or cerebrospinal fluids (CSF)). However, this can take 24–48 hours and is compounded by having a high false-negative^{4,6} and false positive⁷ rates by contaminating pathogens. Molecular detection of specific pathogens is an option but results can be confounded by co-infections and samples need to be obtained from the site of infection which can be both invasive and impractical⁸. Because it is challenging for paediatricians to differentiate between bacterial and viral infection in acute illness, antibiotics are often prescribed as a precautionary measure, contributing to the rise of antimicrobial resistance.

It is clear that reliable biomarkers are urgently needed that distinguish bacterial from viral infection for the purpose of good clinical management and reducing antibiotic use. Host biomarkers, i.e. the physiological changes of the host in response to a specific pathogen, have untapped diagnostic potential and their discovery can be accelerated by the advances in ‘omics’ research, especially in the field of transcriptomics^{9–12} and proteomics^{13–15}. Metabolomics has the added advantage that it is considered to most closely reflect the native phenotype and functional state of a biological system. One *In vivo* animal study revealed that distinct metabolic profiles can be derived from mice infected with different bacteria¹⁶ and several similar studies focusing on meningitis have shown that metabolic profiling of CSF can differentiate between meningitis and negative controls¹⁷, as well as between viral and bacterial meningitis¹⁸. Mason *et al.*¹⁹ demonstrated the possibility of diagnosis and prognosis of tuberculous meningitis with non-invasive urinary metabolic profiles. Metabolic changes in urine can be used to differentiate children with respiratory syncytial virus (RSV) from healthy control, as well as from those with bacterial causes of respiratory distress²⁰.

Lipids are essential structural components of cell membranes and energy storage molecules. Thanks to the advances in lipidomics, a subset of metabolomics, lipids and lipid mediators have been increasingly recognised to play a crucial role in different metabolic pathways and cellular functions, particularly in immunity and inflammation^{21,22}. However, the potential of lipidomics to distinguish bacterial from viral infection in febrile children has never been explored.

In this study, we undertook a lipidomic analysis of plasma taken from febrile children with confirmed bacterial infection ($n = 20$) and confirmed viral infection ($n = 20$) as a proof of concept study. We show that bacterial and viral infection produces distinct profiles in the plasma lipids of febrile children that might be exploited diagnostically.

Methods

Study population and sampling. The European Union Childhood Life-Threatening Infectious Disease Study (EUCLIDS)²³ prospectively recruited patients, aged from 1 month to 18 years, with sepsis or severe focal infection from 98 participating hospitals in the UK, Austria, Germany, Lithuania, Spain and the Netherlands between 2012 and 2015. Plasma and other biosamples were collected to investigate the underlying genetics, proteomics and metabolomics of children with severe infectious disease phenotype.

Infections in Children in the Emergency Department (ICED) study aimed to define clinical features that would predict bacterial illness in children and patterns of proteomics, genomics and metabolomics associated with infections. This study included children aged 0–16 years at Imperial College NHS Healthcare Trust, St Mary’s Hospital, between June 2014 and March 2015²⁴.

The population consisted of children (≤ 17 years old) presenting with fever ≥ 38 °C, with diverse clinical symptoms and a spectrum of pathogens. Both studies were approved by the local institutional review boards (ICED REC No 14/LO/0266 approved by NRES Committee London – Camden & Islington; EUCLIDS REC No 11/LO/1982 approved by NRES Committee London – Fulham). Written informed consent was obtained from parents and assent from children, where appropriate. All methods were performed in accordance with the relevant guidelines and regulations. For the EUCLIDS study, a common clinical protocol agreed by EUCLIDS Clinical Network and approved by the Ethics Committee was implemented at all hospitals.

Patients were divided into those with confirmed bacterial ($n = 20$) and confirmed viral ($n = 20$) infection groups. The bacterial group consisted exclusively of patients with confirmed sterile site culture-positive bacterial infections, and the viral infection group consisted of only patients with culture, molecular or immunofluorescent-confirmed viral infection and having no co-existing bacterial infection.

Blood samples were collected in tubes spray-coated with EDTA at, or as close as possible to, the time of presentation to hospital and plasma obtained by centrifugation of blood samples for 10 mins at 1,300 g at 4 °C. Plasma was stored at -80 °C before being shipped on dry ice to Imperial College London for lipidomic analysis.

Lipidomic analysis. Lipidomic analysis was carried out as previously described²⁵. Briefly, 50 μ l of water were added to 50 μ l of plasma, vortexed and shaken for 5 min at 1,400 rpm at 4 °C. Four hundred μ l of isopropanol containing internal standards (9 in negative mode, 11 for positive mode covering 10 lipid sub-classes) were added for lipid extraction. Samples were shaken at 1,400 rpm for 2 hours at 4 °C then centrifuged at 3,800 g for 10 min. Two aliquots of 100 μ l of the supernatant fluid were transferred to a 96-well plate for ultra-performance liquid chromatography (UPLC) –mass spectrometry (MS) lipidomics analysis in positive and negative mode.

Liquid chromatography separation was carried out using an Acquity UPLC system (Waters Corporation, USA) with an injection volume of 1 μ l and 2 μ l for Positive and Negative ESI, respectively. An Acquity UPLC BEH column (C8, 2.1 \times 100 mm, 1.7 μ m; Waters Corporation, USA) was used for the purpose. Mobile phase A consisted of water/isopropanol/acetonitrile (2:1:1; v:v:v) with the addition of 5 mM ammonium acetate, 0.05% acetic acid and 20 μ M phosphoric acid. Mobile phase B consisted of isopropanol: acetonitrile (1:1; v:v) with the addition of 5 mM ammonium acetate and 0.05% acetic acid. Flow rate was 0.6 ml/min with a total run time of 15 min and the gradient set as starting condition of 1% mobile phase B for 0.1 min, followed by an increase to 30% mobile phase B from 0.1 to 2 min, and to 90% mobile phase B from 2 min to 11.5 min. The gradient was held at 99.99% mobile phase B between 12 and 12.55 min before returning to the initial condition for re-equilibrium.

MS detection was achieved using a Xevo G2-S QToF mass spectrometer (Waters MS Technologies, UK) and data acquired in both positive and negative modes. The MS setting was configured as follows: capillary voltage 2.0 kV for Positive mode, 1.5 kV for Negative mode, sample cone voltage 25 V, source offset 80, source temperature 120 $^{\circ}$ C, desolvation temperature 600 $^{\circ}$ C, desolvation gas flow 1000 L/h, and cone gas flow 150 L/h. Data were collected in centroid mode with a scan range of 50–2000 m/z and a scan time of 0.1 s. LockSpray mass correction was applied for mass accuracy using a 600 pg/ μ L leucine enkephaline (m/z 556.2771 in ESI+, m/z 554.2615 in ESI-) solution in water/acetonitrile solution (1:1; v/v) at a flow rate of 15 μ l/min.

Spectral and statistical analysis. A Study Quality Control sample (SQC) was prepared by pooling 25 μ l of all samples. The SQC was diluted to seven different concentrations, extracted at the same ratio 1:4 with isopropanol and replicates acquired at each concentration at the beginning and end of the run. A Long-Term Reference sample (LTR, made up of pooled plasma samples from external sources) and the SQC were diluted with water (1:1; v:v) and 400 μ L of isopropanol containing internal standards (the same preparation as for the study samples) and injected once every 10 study samples, with 5 samples between a LTR and a SQC. Deconvolution of the spectra was carried out using the XCMS package. Extracted metabolic features were subsequently filtered and only those present with a relative coefficient of variation less than 15% across all SQC samples were retained. Additionally, metabolic features that did not correlate with a coefficient greater than 0.9 in a serial dilution series of SQC samples were removed.

Multivariate data analysis was carried out using SIMCA-P 14.1 (Umetrics AB, Sweden). The dataset was pareto-scaled prior to principal component analysis (PCA) and orthogonal partial least squares discriminate analysis (OPLS-DA). While PCA is an unsupervised technique useful for observing inherent clustering and identifying potential outliers in the dataset, OPLS-DA is a supervised method in which data is modelled against a specific descriptor of interest (in this case viral vs. bacterial infection classes). As for all supervised methods, model validity and robustness must be assessed before results can be interpreted. For OPLS-DA, model quality was assessed by internal cross-validation (Q^2Y -hat value) and permutation testing in which the true Q^2Y -hat value is compared to 999 models with random permutations of class membership. For valid and robust models (positive Q^2Y -hat and permutation p-value < 0.05), metabolic features responsible for class separation were identified by examining the corresponding S-plot (a scatter plot of model loadings and correlation to class) with a cut-off of 0.05.

Metabolite annotation. Short-listed metabolic features were subjected to tandem mass spectrometry in order to obtain fragmentation patterns. Patterns were compared against metabolome databases (Lipidmaps, HMDB, Metlin). Isotopic distribution matching was also checked. In addition, when possible the fragmented patterns were matched against available authentic standards run under the same analytical setting for retention time and MS/MS patterns. Annotation level, according to the Metabolomics Standards Initiative, are summarised in Table 1²⁶.

Single feature ROC curve analysis. Analysis was performed with the web server, MetaboAnalyst 4.0. Sensitivities and specificities of lipids and predicted probabilities for the correct classification were presented as Receiver Operating Characteristic (ROC) curves. The Area Under the Curve (AUC) represents the discriminatory power of the lipids, with the value closest to 1 indicating the better classification.

Feature selection. An 'in-house' variable selection method, forward selection-partial least squares (FS-PLS; <https://github.com/lachlancoin/fspls.git>), was used to identify a small diagnostic signature for distinguishing bacterial and viral infections. FS-PLS identifies a small signature made up non-correlated features. The first iteration of FS-PLS considers the levels of all features (N) and initially fits N univariate regression models. The regression coefficient for each model is estimated using the Maximum Likelihood Estimation (MLE) function, and the goodness of fit is assessed by a t-test. The variable with the highest MLE and smallest p-value is selected first (SV1). Before selecting which of the N-1 remaining variables to use next, the algorithm projects the variation explained by SV1 using Singular Value Decomposition (SVD). The algorithm iteratively fits up to N-1 models, at each step projecting the variation corresponding to the already selected variables, and selecting new variables based on the residual variation. Projecting out the variation of selected features ensures that the final features in the signature are not correlated with each other. The FS-PLS process terminates when the MLE p-value exceeds a pre-defined threshold (p_{thresh}). The final model includes regression coefficients for all selected variables. First, FS-PLS was applied to the abundance values for the short-listed metabolic features identified through OPLS-DA analysis.

An individual's age and sex can impact upon their metabolome greatly. Limma²⁷ was used for differential abundance analysis to identify metabolites that are associated with age or sex. Features were considered to be associated with age or sex if they achieved an FDR p-value lower than 0.05. FS-PLS was re-applied to the dataset after having removed these features and the resulting signature was compared to the signatures from the full dataset.

	m/z	Retention time	Annotation	Annotation level	Ion type	Neutral formula
Lipids/metabolites increased in bacterial infected group	279.231	2.52	FA(18:2)	2	[M – H]-	C18H32O2
	255.232	2.82	FA(16:0)	2	[M – H]-	C16H32O2
	281.247	2.96	FA(18:1)	2	[M – H]-	C18H34O2
	788.545	6.22	PS(18:0/18:1)	2	[M – H]-	C39H74NO8P
	253.216	2.35	FA(16:1)	2	[M – H]-	C16H30O2
	742.54	6.06	PC(16:0/18:2)	2	[M – CH3]-	C42H80NO8P
	716.524	6.75	PE(16:0/18:1)	2	[M – H]-	C39H76NO8P
	583.256	1.18	Bilirubin	2	[M – H]-	C33H36N4O6
	810.53	5.76	PS(18:0/20:4)	2	[M – H]-	C44H78NO10P
	846.624	7.23	PC(18:0/18:1)	2	[M + PO4H2]-	C44H86NO8P
	1068.7	7.80	LacCer(d18:1/24:1)	2	[M + PO4H2]-	C54H101NO13
	770.571	6.78	PC(18:0/18:2)	2	[M – CH3]-	C44H84NO8P
	744.556	6.60	PC(16:0/18:1)	2	[M – CH3]-	C42H82NO8P
	958.589	5.78	LacCer(d18:1/16:0)	2	[M + PO4H2]-	C46H87NO13
	718.54	6.41	PC(16:0/16:0)	2	[M – CH3]-	C40H80NO8P
	742.54	6.90	PE(18:0/18:2)	2	[M – H]-	C41H78NO8P
Lipids/metabolites increased in viral infected group	465.303	2.55	Cholesterol sulfate	2	[M – H]-	C27H46O4S
	465.303	2.61	Cholesterol sulfate	2	[M – H]-	C27H46O4S
	909.551	5.56	PI(18:0/22:6)	2	[M – H]-	C49H83O13P
	861.55	5.75	PI(18:0/18:2)	2	[M – H]-	C45H83O13P
	797.655	7.78	SM(d18:1/24:1)	2	[M – CH3]-	C47H93N2O6P
	339.231	2.66	UNKNOWN1	4		
	772.529	6.49	PE1	3	[M – H]-	C45H76NO7P
	897.648	8.12	SM(d18:1/23:0)	2	[M + PO4H2]-	C46H93N2O6P
	239.157	0.87	UNKNOWN2	4		
	886.609	6.31	SHexCer(d42:3)	2	[M – H]-	C48H89NO11S
	554.346	1.86	LPC(16:0/0:0)	2	[M + CH3COO]-	C24H50NO7P
	799.671	8.41	SM(d18:1/24:0)	2	[M – CH3]-	C47H95N2O6P
	750.545	7.24	PE2	3	[M – H]-	C41H78NO7P

Table 1. Metabolic features changed in bacterial and viral group. FA: fatty acid; PE: glycerophosphatidylethanolamine; PC: glycerophosphocholine; PS: glycerophosphoserine; LacCer: lactosylceramide; PI: glycerophosphoinositol; SM: sphingomyelin; LPC: Lysophosphatidylcholine; SHexCer: Sulfatides.

The disease risk score (DRS) was calculated for the 3 metabolite signature. The DRS translates the abundance values of the features in the signature into a single value, indicating the disease group of the sample¹¹.

The sensitivity and specificity of the lipid signature were presented as a receiver operating characteristic (ROC) curve with the 95% confidence regions calculated through bootstrap analysis with 500 iterations.

Results

Patient characteristics. The baseline characteristics were divided into those with definitive bacterial and definitive viral infection, summarised in Table 2. When selecting patient samples, patient characteristics were matched as much as possible to ensure no particular factor would confound the model. There was no significant difference in ages between the two groups ($p = 0.97$). Both groups had similar sex split. Seven from definitive bacterial infection group and 6 from the definitive viral infection group were admitted to the Paediatric Intensive Care Unit (PICU). A range of pathogens was present in each group.

Plasma lipidome can differentiate bacterial from viral infection. PCA was conducted first to evaluate the data, visualise dominant patterns, and identify outliers within populations (Fig. 1). The same outlier sample was present in both negative (Fig. 1A) and positive (Fig. 1B) polarity datasets and as such, was removed from subsequent analysis. SQC samples were tightly grouped together in the PCA scatter plot, indicating minimum analytical variability throughout the run.

OPLS-DA, a supervised PCA method, was carried out on both positive and negative polarity datasets. In the positive polarity mode no model was successfully built to distinguish between viral and bacterial infection groups (data not shown). However, in the negative polarity dataset, an OPLS-DA model separated bacterial infected samples from viral infected samples (with 3891 features). The robustness of the model was characterised by $R^2X(\text{cum}) = 0.565$, $R^2Y\text{-hat}(\text{cum}) = 0.843$ and $Q^2Y\text{-hat}(\text{cum}) = 0.412$ and permutation $p\text{-value} = 0.01$ (999 tests). Cross-validated scores plot using the whole lipidome dataset indicated bacterial infected samples were more prone to miss-classification than viral infected samples (Fig. 2).

Lipid changes were not the same in the bacterial and viral infected groups. Metabolic features contributing to the separation of the model are plotted in Fig. 3 and summarised in Table 1. Some species of

Patients with confirmed	Bacterial infection (N = 20)	Viral infection (N = 20)	P value
Age, median (range), month	9 (1–102)	8 (1–93)	p = 0.48
Male, No. (%)	11 (55)	10 (50)	—
White race, No./total (%)	14/19 (74)	11/20 (55)	—
Time from symptoms to blood sampling, median (range), day	2 (0–9)	3 (0–15)	p = 0.16
Intensive care, No. (%)	7 (35)	6 (30)	—
Fatalities, No.	1	0	—
Pathogen* (#cases)	Coliform (1) <i>B. pertussis</i> (2) <i>E. coli</i> (2) <i>S. Pneumoniae</i> (3) <i>S. aureus</i> (1) <i>E. cloacae</i> (1) <i>N. Meningitidis</i> (8) <i>K. Kingae</i> (1) <i>Klebsiella oxytoca</i> (1) <i>Group A streptococcus</i> (1)**	Enterovirus (3) Influenza A (2) Parechovirus (1) Respiratory syncytial virus (5) Rhinovirus (3) Adenovirus (4) Human Metapneumovirus (1) Parainfluenza virus (1) Human herpesvirus 6 (1) Herpes simplex virus (1) Rotavirus (1)	
Source of the samples	St. Mary's Hospital (2) Alder Hey Children's NHS Foundation (3) Poole Hospital NHS Foundation Trust (2) Nottingham University Hospitals (2) Medical University of Graz (1) General Hospital of Leoben (1) Hospital Clinico Univeritario de Santiago (5) Hospital Universitario 12 de Octubre (2) Complejo Hospitalario de Jaen (1) Erasmus MC (1)	St Mary's Hospital (11) Newcastle Upon Tyne Hospitals NHS (1) Cambridge University Hospitals NHS Foundation Trust (2) Great Ormond Street Hospital (1) Nottingham University Hospitals (2) Hospital Clinico Univeritario de Santiago (2) Erasmus MC (1)	

Table 2. Demographic and clinical patient characteristic. *Some patients are co-infected with more than one pathogen. **The patient with Group A *streptococcus* was excluded from the subsequent data analysis as being an outlier.

glycerophosphoinositol, monoacylglycerophosphocholine, sphingomyelin and sulfatide were higher in the viral group when compared to the bacterial group, while some species of fatty acids, glycerophosphocholine, glycerophosphoserine and lactosylceramide were higher in bacterial infection when compared with viral infection. Bilirubin and cholesterol sulfate, although not lipids, were detected by lipidomic analysis, and these were higher in the bacterial and viral groups when compared to the other group, respectively.

Evaluation of diagnostic potential of metabolic biomarkers. ROC curve analysis was performed to evaluate the diagnostic potential of these lipids in distinguishing bacterial from viral infection. Out of all discriminatory lipids, PC (16:0/16:0), unknown feature m/z 239.157 and PE (16:0/18:2) generated the highest AUCs of 0.774 (CI, 0.6–0.902), 0.721 (CI, 0.545–0.871) and 0.705 (CI, 0.52–0.849), respectively (Fig. 4).

FS-PLS was initially carried out on the abundance values for all 28 shortlisted features. A signature was identified made up the following 3 lipids: SHexCer(d42:3); PC (16:0/16:0); and LacCer(d18:1/24:1). The impacts of age and sex on the feature selection process were explored. With a false discovery rate (FDR) of 0.05, 5 out of the 28 features were identified as being significantly differentially abundant between samples above or below the median age. None of the 28 features were identified as being significantly differentially abundant between males and females. The 5 features that were associated with age were removed and FS-PLS was re-ran on the filtered dataset. The same 3-metabolite signature (SHexCer(d42:3), PC(16:0/16:0), LacCer(d18:1/24:1)) was identified, showing that the signature is robust to age effects.

This signature achieved an improved ROC curve with AUC of 0.911 (95% confidence interval: 0.81–0.98) when compared with those generated from individual lipids. The ROC curve and confidence intervals calculated through bootstrapping are shown in Fig. 5. Figure 6 shows the disease risk scores for definitive bacterial and definitive viral samples with points overlaid to indicate the sex or age (above or below median) of the sample.

Discussion

We have shown that differences in the host lipidome are induced by bacterial and viral infections. While differences in host responses between viral and bacterial infections have been previously reported, for example as differential expression of proteins, RNAs and level of metabolites^{9–14,20}, there have been no claims in relation to the lipidome changes in carefully-phenotyped samples. Although age is known to affect metabolism²⁸, it is important to note the metabolic changes associated with infection described herein, were consistent among samples from patients whose age ranged from 1 month to 9 years old.

Some species of glycerophosphoinositol, sphingomyelin, lysophosphatidylcholine and cholesterol sulfate were higher in the confirmed virus-infected group when compared with bacterial infected group, while some species of fatty acids, glycerophosphocholine, glycerophosphoserine, lactosylceramide and bilirubin were higher in cases with confirmed bacterial infection when compared with viral infection.

The important effects of infection on fatty acid metabolism have been highlighted by Munger *et al.* who demonstrated human cytomegalovirus (HCMV) up-regulated fatty acid biosynthesis in infected host cells.




Figure 1. Principal components analysis (PCA) of lipidomics dataset. **(A)** Scatter plot of PCA model from data acquired in negative polarity mode. **(B)** Scatter plot of PCA model from data acquired in positive polarity mode. Quality control samples are shown in red, bacterial infected samples are shown in blue and viral infected samples shown in green.




Figure 2. The scatter plot of the cross-validated score vectors showing the clustering of definitive bacterial infected samples (green dots) from definitive viral infected samples (blue dots).

Pharmacologically inhibition of fatty acid biosynthesis suppressed viral replication for both HCMV and influenza A virus²⁹. The importance of fatty acid biosynthesis may reflect its essential role in viral envelopment during viral replication. Rhinovirus induced metabolic reprogramming in host cell by increasing glucose uptake and indicated a shift towards lipogenesis and/or fatty acid uptake³⁰. In our study, fatty acids linoleic acid (FA 18:2), palmitic acid (FA 16:0), oleic acid (FA 18:1) and palmitoleic acid (FA 16:1) were lower in viral infection when compared to bacterial infection, and may reflect enhanced lipogenesis and fatty acid uptake in the host cell during viral replication.

The increase in cholesterol sulfate observed may reflect changes in cellular lipid biosynthesis and T cell signaling during viral infection. Cholesterol sulfate is believed to play a key role as a membrane stabiliser³¹ and can also act to modulate cellular lipid biosynthesis³² and T cell receptor signal transduction³³. Gong *et al.* demonstrated that cholesterol sulfate was elevated in the serum of piglets infected with swine fever virus³⁴. Taken together, these observations indicate that this compound could be a marker of viral infection.

Higher level of sphingomyelin SM(d18:1/24:1), SM(d18:1/23:0) and SM(d18:1/24:0), and lysophosphocholine LPC (16:0) upon viral infection may also be linked to viral replication in infected cells. Accumulation of cone-shaped lipids, such as LPC in one leaflet of the membrane bilayer induces membrane curvature required for virus budding³⁵. It is known that viral replication, for example in the case of dengue virus, induces dramatic changes in infected cells, including sphingomyelin, to alter the curvature and permeability of membranes³⁶. Furthermore, the altered levels of sphingomyelin can be partially explained by elevated cytokine levels during bacterial infection, such as TNF- α ³⁷, which can activate sphingomyelinase, hydrolysing sphingomyelin to ceramide³⁸. Hence, sphingomyelin may be a class of lipids that plays a role in both viral and bacterial infection.

Lactosylceramide LacCer(d18:1/24:1) and LacCer (d18:1/16:0) were higher in bacterial infection in comparison to viral infection. Lactosylceramide, found in microdomains on the plasma membrane of cells, is a glycosphingolipid consisting of a hydrophobic ceramide lipid and a hydrophilic sugar moiety. Lactosylceramide plays an important role in bacterial infection by serving as a pattern recognition receptors (PRRs) to detect pathogen-associated molecular patterns (PAMPs). Lactosylceramide composed of long chain fatty acid chain C24, such as LacCer(d18:1/24:1) increased in our study, is essential for formation of LacCer-Lyn complexes on neutrophils, which function as signal transduction platforms for α M β 2 integrin-mediated phagocytosis³⁹.

Other lipids that were changed in our study, such as sulfatides and glycerophosphocholines, may also play an important role in bacterial infection. Sulfatides are multifunctional molecules involved in various biological process, including




Figure 3. Manhattan-style plot of the 3891 lipid features detected by lipid-positive mode UPLC-MS with 40 features showing a significant association with infection type (as determined by model S-plot) highlighted and annotated. Y axis $\text{Sign}(p) \times P$ is the loadings of the OPLS-DA (i.e. modelled covariance $p[1]$). *Cholesterol sulfate – isomers due to different position of the sulfate.




Figure 4. Receiver operator characteristic (ROC) analysis based on single lipids. ROC curve analysis of top 3 lipids PC (16:0/16:0) (A), unknown feature (m/z 239.157) (B) and PE (16:0/18:2) (C) which gave with highest Area Under the Curve (AUC) values.

immune system regulation and during infection⁴⁰. Sulfatides can act as glycolipid receptors that attach bacteria, such as *Escherichia coli*⁴¹, *Mycoplasma hyopneumoniae*⁴² and *Pseudomonas aeruginosa*⁴³ to the mucosal surfaces. Five glycerophosphocholine species including PC(16:0/18:2), PC(18:0/18:1), PC(18:0/18:2), PC(16:0/16:0) and PC(16:0/18:1) were higher in bacterial infected samples when compared with viral infected samples. Glycerophosphocholine was elevated in a lipidomics study looking at plasma from tuberculosis patients⁴⁴, however, the exact role of glycerophosphocholine remains elusive. Bilirubin is detected as a consequence of breadth of lipidome coverage, and its role in infection is unclear. The lipid species identified in this study present an opportunity for further mechanistic study to understand the host responses in bacterial or viral infection.

A combination of three lipids achieved a strong area under the receiver operating characteristic (ROC) curve of 0.911 (95% CI 0.81 to 0.98). Similar approaches have been taken using routine laboratory parameters and more recently gene expression where 2-gene transcripts achieved an ROC AUC of 0.95 (95% CI 0.94-1)¹¹. The relevance of our data is that they provide the potential for a rapid diagnostic test with which clinicians could distinguish bacterial from viral infection in febrile children.

The study has limitations. Firstly, we were unable to annotate 4 of the 29 discriminatory features, of which two were assigned with only a broad lipid class by identifying the head group (PE). The unknown feature with m/z of 239.157 achieved the second highest AUC for ROC curve analysis on an individual basis. The unknown identity prevents this feature from being a potential marker and hinders biological understanding. This feature, however, was not included in the final 3-lipid panel that gave the highest AUC. Secondly, the sample size in this pilot study is small. Validation studies using quantitative assay are now required to confirm the findings. In addition, in larger validation studies, we will look into the signature of specific pathogens, and potentially co-infection by multiple pathogens.




Figure 5. Receiver operator characteristic (ROC) analysis based on 3-lipid signature. A combination of SHexCer(d42:3), PC (16:0/16:0) and LacCer(d18:1/24:1) achieved AUC of 0.911 (CI 95% 0.81–0.98).




Figure 6. Boxplots comparing the Disease Risk Score (DRS) for definitive bacterial and definitive viral samples. The DRS was calculated using abundance values from the 3-metabolite signature identified by FS-PLS. Plot A shows points coloured according to the sex of the sample and plot B shows points coloured according to whether the sample was above or below the median age (9 months).

This is the first lipidomics study carried out on plasma taken from febrile children for the purpose of distinguishing bacterial from viral infection. It demonstrates the potential of this approach to facilitate effective clinical management by rapidly diagnosing bacterial infection in paediatrics.

Data availability

The datasets generated and/or analysed during the current study are available from corresponding author on a reasonable request.

Received: 21 June 2019; Accepted: 3 November 2019;

Published online: 27 November 2019

References

- Hay, A. D., Heron, J. & Ness, A. The prevalence of symptoms and consultations in pre-school children in the Avon Longitudinal Study of Parents and Children (ALSPAC): a prospective cohort study. *Fam. Pract.* **22**, 367–374 (2005).
- Alpern, E. R. *et al.* Epidemiology of a Pediatric Emergency Medicine Research Network. *Pediatr. Emerg. Care* **22**, 689–699 (2006).

3. Hsiao, A. L. *et al.* Incidence and predictors of serious bacterial infections among 57- to 180-day-old infants. *Pediatrics* **117**, 1695–701 (2006).
4. Craig, J. C. *et al.* The accuracy of clinical symptoms and signs for the diagnosis of serious bacterial infection in young febrile children: prospective cohort study of 15 781 febrile illnesses. *BMJ* **340**, c1594 (2010).
5. Nijman, R. G. *et al.* Clinical prediction model to aid emergency doctors managing febrile children at risk of serious bacterial infections: diagnostic study. *BMJ* **346**, f1706 (2013).
6. Le Doare, K. *et al.* Very low rates of culture-confirmed invasive bacterial infections in a prospective 3-year population-based surveillance in Southwest London. *Arch. Dis. Child.* **99**, 526–31 (2014).
7. Hall, K. K. & Lyman, J. A. Updated review of blood culture contamination. *Clin. Microbiol. Rev.* **19**, 788–802 (2006).
8. Gill, P. J., Richardson, S. E., Ostrow, O. & Friedman, J. N. Testing for Respiratory Viruses in Children. *JAMA Pediatr.* **171**, 798 (2017).
9. Ramilo, O. & Mejías, A. Shifting the Paradigm: Host Gene Signatures for Diagnosis of Infectious Diseases. *Cell Host Microbe* **6**, 199–200 (2009).
10. Tsalik, E. L. *et al.* Host gene expression classifiers diagnose acute respiratory illness etiology. *Sci. Transl. Med.* **8**, 322ra11–322ra11 (2016).
11. Herberg, J. A. *et al.* Diagnostic Test Accuracy of a 2-Transcript Host RNA Signature for Discriminating Bacterial vs Viral Infection in Febrile Children. *JAMA* **316**, 835 (2016).
12. Mahajan, P. *et al.* Association of RNA Biosignatures With Bacterial Infections in Febrile Infants Aged 60 Days or Younger. *JAMA* **316**, 846 (2016).
13. Oved, K. *et al.* A Novel Host-Proteome Signature for Distinguishing between Acute Bacterial and Viral Infections. *PLoS One* **10**, e0120012 (2015).
14. Eden, E. *et al.* Diagnostic accuracy of a TRAIL, IP-10 and CRP combination for discriminating bacterial and viral etiologies at the Emergency Department. *J. Infect.* **73**, 177–180 (2016).
15. Ashkenazi-Hoffnung, L. *et al.* A host-protein signature is superior to other biomarkers for differentiating between bacterial and viral disease in patients with respiratory infection and fever without source: a prospective observational study. *Eur. J. Clin. Microbiol. Infect. Dis.* **37**, 1361–1371 (2018).
16. Hoerr, V. *et al.* Gram-negative and Gram-Positive Bacterial Infections Give Rise to a Different Metabolic Response in a Mouse Model. *J. Proteome Res.* **11**, 3231–3245 (2012).
17. Chatterji, T. *et al.* Proton NMR metabolic profiling of CSF reveals distinct differentiation of meningitis from negative controls. *Clin. Chim. Acta* **469**, 42–52 (2017).
18. Coen, M., O'Sullivan, M., Bubbs, W. A., Kuchel, P. W. & Sorrell, T. Proton nuclear magnetic resonance-based metabolomics for rapid diagnosis of meningitis and ventriculitis. *Clin. Infect. Dis.* **41**, 1582–90 (2005).
19. Mason, S. *et al.* A putative urinary biosignature for diagnosis and follow-up of tuberculous meningitis in children: outcome of a metabolomics study disclosing host–pathogen responses. *Metabolomics* **12**, 110 (2016).
20. Adamko, D. J., Saude, E., Bear, M., Regush, S. & Robinson, J. L. Urine metabolomic profiling of children with respiratory tract infections in the emergency department: a pilot study. *BMC Infect. Dis.* **16**, 439 (2016).
21. Arita, M. Mediator lipidomics in acute inflammation and resolution. *J. Biochem.* **152**, 313–319 (2012).
22. Zhang, C. *et al.* Lipid metabolism in inflammation-related diseases. *Analyst* **143**, 4526–4536 (2018).
23. Martínón-Torres, F. *et al.* Life-threatening infections in children in Europe (the EUCLIDS Project): a prospective cohort study. *Lancet Child Adolesc. Heal.* **2**, 404–414 (2018).
24. Levin, M. *et al.* Adverse effects of saline albumin fluid bolus in resuscitation: evidence from the FEAST Trial. *Lancet. Resp Med.* **7**, p581–593 (2019).
25. Izzi-Engbeaya, C. *et al.* The effects of kisspeptin on β -cell function, serum metabolites and appetite in humans. *Diabetes, Obes. Metab.* **20**, 2800–2810 (2018).
26. Sumner, L. W. *et al.* Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). *Metabolomics* **3**, 211–221 (2007).
27. Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* **43**, e47–e47 (2015).
28. Hines, R. N. The ontogeny of drug metabolism enzymes and implications for adverse drug events. *Pharmacol Ther.* **118**, 250–267 (2008).
29. Munger, J. *et al.* Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. *Nat. Biotechnol.* Vol. 26 (2008).
30. Gualdoni, G. A. *et al.* Rhinovirus induces an anabolic reprogramming in host cell metabolism essential for viral replication. *Proc Natl Acad Sci USA* **115**(30), E7158–E7165 (2018).
31. Strott, C. A. & Higashi, Y. Cholesterol sulfate in human physiology: what's it all about? *J. Lipid Res.* **44** (2003).
32. Festa, A. *et al.* Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. *Circulation* **111**, 3465–3472 (2005).
33. Wang, F., Beck-García, K., Zorzín, C., Schamel, W. W. A. & Davis, M. M. Inhibition of T cell receptor signaling by cholesterol sulfate, a naturally occurring derivative of membrane cholesterol. *Nat. Immunol.* **17**, 844–850 (2016).
34. Gong, W. *et al.* Serum Metabolomic Profiling of Piglets Infected with Virulent Classical Swine Fever Virus. *Front. Microbiol.* **8**, 731 (2017).
35. Heaton, N. S. & Randall, G. Multifaceted roles for lipids in viral infection. *Trends Microbiol.* **19**, 368–375 (2011).
36. Perera, M. N. *et al.* Ceramide channels: influence of molecular structure on channel formation in membranes. *Biochim. Biophys. Acta* **1818**, 1291–301 (2012).
37. Holub, M. *et al.* Cytokines and chemokines as biomarkers of community-acquired bacterial infection. *Mediators Inflamm.* **2013**, 190145 (2013).
38. Maceyka, M. & Spiegel, S. Sphingolipid metabolites in inflammatory disease. *Nature* **510**, 58–67 (2014).
39. Ekyalongo, R. C., Nakayama, H., Kina, K., Kaga, N. & Iwabuchi, K. Organization and functions of glycolipid-enriched microdomains in phagocytes. *Biochim. Biophys. Acta - Mol. Cell Biol. Lipids* **1851**, 90–97 (2015).
40. Takahashi, T. & Suzuki, T. Role of sulfatide in normal and pathological cells and tissues. *J. Lipid Res.* **53**, 1437–50 (2012).
41. Jansson, L. *et al.* Sulfatide Recognition by Colonization Factor Antigen CS6 from Enterotoxigenic Escherichia coli. *PLoS One* **4**, e4487 (2009).
42. Zhang, Q., Young, T. F. & Ross, R. F. Glycolipid receptors for attachment of Mycoplasma hyopneumoniae to porcine respiratory ciliated cells. *Infect. Immun.* **62**, 4367–73 (1994).
43. Yagci, A., Sener, B., Suzuki, Y. & Ahmed, K. Sulfatide mediates attachment of Pseudomonas aeruginosa to human pharyngeal epithelial cells. *New Microbiologica* **30** (2007).
44. Wood, P. L., Tippireddy, S. & Feriante, J. Plasma lipidomics of tuberculosis patients: altered phosphatidylcholine remodeling. *Futur. Sci. OA* **4**, FSO255 (2018).

Acknowledgements

This work was partially supported by the European Seventh Framework Programme for Research and Technological Development (FP7) under EUCLIDS Grant Agreement no. 279185. ICED: The Research was supported by the National Institute for Health Research Biomedical Research Centre based at Imperial College. This work was further supported by the Medical Research Council and National Institute for Health Research [grant number MC_PC_12025] through funding for the MRC-NIHR National Phenome Centre, infrastructure support was provided by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Imperial NHS Healthcare Trust. MK acknowledges funding from the Wellcome Trust (Sir Henry Wellcome Fellowship grant 206508/Z/17/Z). This paper is independent research funded by the NIHR Imperial BRC.

Author contributions

X.W., S.C., C.S., and Matthew L conducted lipidomics analysis. H.J. and M.K. performed feature selection analysis. R.N. selected samples from the cohort for analysis. M.M. conceived the idea and supervised the project. X.W. wrote the manuscript. M.E., J.H., E.D.C., S.C.P., W.Z., M.F., R.G., F.M.-T., L.J.S., A.J.P., C.F., T.T.K., S.A., Michael L are principal investigators of the EUCLIDS study and recruited patients, some of which were included in this study. I.M. is the principal investigators of the ICED study. All authors read and approved the final manuscript.

Competing interests

Michiel Van der Flier received CSL Behring Grant for *in vitro* testing novel antibody preparation and Shire grant for Quality improvement PID outpatient clinic, also has Thermo Fisher Educational event speaker honorarium. Andrew J Pollard chairs the UK department of Health and Social Care's (DHSC) Joint Committee on Vaccination and Immunisation and the EMA Scientific Advisory Group on vaccines, and he is a member of WHO's Strategic Advisory Group of Experts. The views expressed in the publication are those of the author(s) and not necessarily those of the DHSC, NIHR or WHO. Other authors declare no potential conflict of interest.

Additional information

Correspondence and requests for materials should be addressed to M.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019

Consortia

EUCLIDS consortium

Stuart Gormley¹, Shea Hamilton¹, Bernardo Hourmat¹, Clive Hoggart¹, Vanessa Sancho-Shimizu¹, Victoria Wright¹, Amina Abdulla¹, Paul Agapow¹, Maeve Bartlett¹, Evangelos Bellos¹, Hariklia Eleftherohorinou¹, Rachel Galassini¹, David Inwald¹, Meg Mashbat¹, Stefanie Menikou¹, Sobia Mustafa¹, Simon Nadel¹, Rahmeen Rahman¹, Clare Thakker¹, Lachlan M. J. Coin¹, S. Bokhandi²⁰, Sue Power²⁰, Heather Barham²⁰, Dr N Pathan²¹, Jenna Ridout²¹, Deborah White²¹, Sarah Thurston²¹, S. Faust²², S. Patel²², Jenni McCorkell²², P. Davies²³, Lindsey Crate²³, Helen Navarra²³, Stephanie Carter²³, R. Ramaiah²⁴, Rekha Patel²⁴, Catherine Tuffrey²⁵, Andrew Gribbin²⁵, Sharon McCready²⁵, Mark Peters²⁶, Katie Hardy²⁶, Fran Standing²⁶, Lauren O'Neill²⁶, Eugenia Abelake²⁶, Akash Deep²⁷, Eniola Nsirim²⁷, Louise Willis²⁸, Zoe Young²⁸, C. Royad²⁹, Sonia White²⁹, P. M. Fortune³⁰, Phil Hudnott³⁰, Fernando Álvez González¹⁴, Ruth Barral-Arca^{14,31}, Miriam Cebey-López¹⁴, María José Curras-Tuala^{2,14}, Natalia García¹⁴, Luisa García Vicente¹⁴, Alberto Gómez-Carballea^{14,31}, Jose Gómez Rial¹⁴, Andrea Grela Beiroa¹⁴, Antonio Justicia Grande¹⁴, Pilar Leboráns Iglesias¹⁴, Alba Elena Martínez Santos¹⁴, Federico Martín-Torres¹⁴, Nazareth Martín-Torres¹⁴, José María Martín Sánchez¹⁴, Beatriz Morillo Gutiérrez¹⁴, Belén Mosquera Pérez¹⁴, Pablo Obando Pacheco¹⁴, Jacobo Pardo-Seco^{14,31}, Sara Pischredda^{14,31}, Irene Rivero Calle¹⁴, Carmen Rodríguez-Tenreiro¹⁴, Lorenzo Redondo-Collazo¹⁴, Antonio Salas Ellacuriagal^{14,31}, Sonia Serén Fernández¹⁴, María del Sol Porto Silva¹⁴, Ana Vega^{14,32}, Lucía Vilanova Trillo¹⁴, Antonio Salas^{14,31}, Susana Beatriz Reyes³³, María Cruz León León³³, Álvaro Navarro Mingorance³³, Xavier Gabaldó Barrios³³, Eider Oñate Vergara³⁴, Andrés Concha Torre³⁵, Ana Vivanco³⁵, Reyes Fernández³⁵, Francisco Giménez Sánchez³⁶, Miguel Sánchez Forte³⁶, Pablo Rojo³⁷, J. Ruiz Contreras³⁷, Alba Palacios³⁷, Cristina Epalza Ibarrondo³⁷, Elizabeth Fernández Cooke³⁷, Marisa Navarro³⁸, Cristina Álvarez Álvarez³⁸, María José Lozano³⁸, Eduardo Carreras³⁹, Sonia Brió Sanagustín³⁹, Olaf Neth⁴⁰, Ma del Carmen Martínez Padilla⁴¹, Luis Manuel Prieto Tato⁴², Sara Guillén⁴², Laura Fernández Silveira⁴³, David Moreno⁴⁴, A. M. Tutu van Furth⁴⁵, N. P. Boeddha⁴⁶, G. J. A. Driessen⁴⁶, M. Emonts^{46,47,48}, J. A. Hazelzet⁴⁶, D. Pajkrt¹⁸, E. A. M. Sanders⁴⁹, D. van de Beek⁵⁰, A. van der Ende⁵⁰, H. L. A. Philipsen⁴⁵, A. O. A. Adeel⁵¹, M. A. Breukels⁵², D. M. C. Brinkman⁵³, C. C. M. M. de Korte⁵⁴, E. de Vries^{55,56}, W. J. de Waal⁵⁷, R. Dekkers⁵⁷, A. Dings-Lammertink⁵⁸, R. A. Doedens⁵⁹, A. E. Donker⁶⁰, M. Dousma⁶¹, T. E. Faber⁶², G. P. J. M. Gerrits⁶³, J. A. M. Gerver⁶⁴, J. Heidema⁶⁵, J. Homan-van der Veen⁶⁶, M. A. M. Jacobs⁶⁷, N. J. G. Jansen⁴⁹, P. Kawczynski⁶⁸, K. Klucovska⁶⁹, M. C. J. Kneyber⁷⁰, Y. Koopman-Keemink⁷¹, V. J. Langenhorst⁷², J. Leusink⁷³, B. F. Loza⁷⁴, I. T. Merth⁷⁵, C. J. Miedema⁷⁶, C. Neeleman⁴⁵, J. G. Noordzij⁷⁷, C. C. Obihara⁷⁸, A. L. T. van Overbeek – van Gils⁷⁹, G. H. Poortman⁸⁰, S. T. Potgieter⁸¹, J. Potjewijd⁸², P. P. R. Rosias⁸³, T. Sprong⁶³, G. W. ten Tusscher⁸⁴, B. J. Thio⁸⁵, G. A. Tramper-Stranders⁸⁶, M. van Deuren⁴⁵, H. van der Meer¹⁴, A. J. M. van Kuppevelt⁸⁷, A. M. van Wermeskerken⁸⁸, W. A. Verwijs⁸⁹, T. F. W. Wolfs⁴⁷, Philipp Agyeman⁹⁰, Christoph Aebi⁹⁰, Christoph Berger⁹⁰, Philipp Agyeman⁹⁰, Christoph Aebi⁹⁰, Eric Giannoni^{91,92}, Martin Stocker⁹³, Klara M. Posfay-Barbe⁹⁴, Ulrich Heininger⁹⁵, Sara Bernhard-Stirnemann⁹⁶, Anita Niederer-Loher⁹⁷, Christian Kahlert⁹⁷, Paul Hasters⁹⁸, Christa Relly⁹⁹, Walter Baer¹⁰⁰, Christoph Berger⁹⁹, Hannah Frederick¹⁰¹, Rebecca Jennings¹⁰¹, Joanne Johnston¹⁰¹, Rhian Kenwright¹⁰¹, Elli Pinnock¹⁷, Rachel Agbeko^{5,6}, Fatou Secka¹⁹, Kalifa Bojang¹⁹, Isatou Sarr¹⁹, Ngange Kebbeh¹⁹, Gibbi Sey¹⁹, Momodou, Saidy khan¹⁹, Fatoumata Cole¹⁹, Gilleh Thomas¹⁹, Martin Antonio¹⁹, Daniela S. Klobassa¹¹, Alexander Binder¹¹, Nina A. Schweintzger¹¹, Manfred Sagmeister¹¹, Hinrich Baumgart¹⁰², Markus Baumgartner¹⁰³, Uta Behrends¹⁰⁴, Ariane Biebl¹⁰⁵, Robert Birnbacher¹⁰⁶, Jan-Gerd Blanke¹⁰⁷, Carsten Boelke¹⁰⁸, Kai Breuling¹⁰⁴, Jürgen Brunner¹⁰⁹, Maria Buller¹¹⁰, Peter Dahlem¹¹¹, Beate Dietrich¹¹², Ernst Eber¹¹³, Johannes Elias¹¹⁴, Josef Emhofer¹⁰³, Rosa Etschmaier¹¹⁵, Sebastian Farr¹¹⁶, Ylenia Girtler¹¹⁷, Irina Grigorow¹¹⁸, Konrad Heimann¹¹⁹, Ulrike Ihm¹²⁰, Zdenek Jaros¹²¹, Hermann Kalhoff¹²², Wilhelm Kaufersch¹²³, Christoph Kemen¹²⁴, Nina Klocker¹²⁵, Bernhard Köster¹²⁶, Benno Kohlmaier¹²⁷, Eleni Komini¹²⁸, Lydia Kramer¹⁰⁴, Antje Neubert¹²⁹, Daniel Ortner¹³⁰, Lydia Pescollderung¹¹⁷, Klaus Pfurtscheller¹³¹, Karl Reiter¹³², Goran Ristic¹³³, Siegfried Rödl¹³¹, Andrea Sellner¹²⁷, Astrid Sonnleitner¹²⁷, Matthias Sperl¹³⁴, Wolfgang Stelzl¹³⁵, Holger Till¹⁰², Andreas Trobisch¹²⁷, Anne Vierzig¹³⁶, Ulrich Vogel¹¹³, Christina Weingarten¹³⁷, Stefanie Welke¹³⁸, Andreas Wimmer¹³⁹, Uwe Wintergerst¹⁴⁰, Daniel Wüller¹⁴¹, Andrew Zaunschirm¹⁴², Ieva Ziuraite¹⁴³ & Veslava Žukovskaja¹⁴³

²⁰Poole Hospital NHS Foundation Trust, Poole, United Kingdom. ²¹Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom. ²²University Hospital Southampton, Southampton, United Kingdom. ²³Nottingham University Hospital NHS Trust, Nottingham, United Kingdom. ²⁴University Hospitals of Leicester NHS Trust, Leicester, United Kingdom. ²⁵Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom. ²⁶Great Ormond Street Hospital, London, United Kingdom. ²⁷King's College Hospital NHS Foundation Trust, London, United Kingdom. ²⁸Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom. ²⁹Kettering General Hospital NHS Foundation Trust, Kettering, United Kingdom. ³⁰Central Manchester NHS Trust, Manchester, United Kingdom. ³¹Unidade de Xenética, Departamento de Anatomía Patolóxica e Ciencias Forenses, Instituto de Ciencias Forenses, Facultade de Medicina, Universidade de Santiago de Compostela, and GenPop Research Group, Instituto de Investigaciones Sanitarias (IDIS), Hospital Clínico Universitario de Santiago, Galicia, Spain. ³²Fundación Pública Galega de Medicina Xenómica, Servizo Galego de Saúde (SERGAS), Instituto de Investigaciones Sanitarias (IDIS), and Grupo de Medicina Xenómica, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain. ³³Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain. ³⁴Hospital de Donostia, San Sebastián, Spain. ³⁵Hospital Universitario Central de Asturias, Asturias, Spain. ³⁶Complejo Hospitalario Torrecárdenas, Almería, Spain. ³⁷Hospital Universitario 12 de Octubre, Madrid, Spain. ³⁸Hospital General Universitario Gregorio Marañón, Madrid, Spain. ³⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. ⁴⁰Hospital Universitario Virgen del Rocío, Sevilla, Spain. ⁴¹Complejo Hospitalario de Jaén, Jaén, Spain. ⁴²Hospital Universitario de Getafe, Madrid, Spain. ⁴³Hospital Universitario y Politécnico de La Fe, Valencia, Spain. ⁴⁴Hospital Regional Universitario Carlos Haya, Málaga, Spain. ⁴⁵Vrije Universiteit University Medical Center, Amsterdam, The Netherlands. ⁴⁶Erasmus Medical Center – Sophia Children's Hospital, Rotterdam, The Netherlands. ⁴⁷Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom. ⁴⁸Paediatric Infectious Diseases and Immunology Department, Newcastle upon Tyne Hospitals Foundation Trust, Great North Children's Hospital, Newcastle upon Tyne, United Kingdom. ⁴⁹University Medical Center Utrecht – Wilhelmina Children's Hospital, Utrecht, The Netherlands. ⁵⁰Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. ⁵¹Kenemer Gasthuis, Haarlem, The Netherlands. ⁵²Elkerliek Hospital, Helmond, The Netherlands. ⁵³Alrijne Hospital, Leiderdorp, The Netherlands. ⁵⁴Beatrix Hospital, Gorinchem, The Netherlands. ⁵⁵Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands. ⁵⁶Diakonessenhuis, Utrecht, The Netherlands. ⁵⁷Maasziekenhuis Pantein, Boxmeer, The Netherlands. ⁵⁸Gelre Hospitals, Zutphen, The Netherlands. ⁵⁹Martini Hospital, Groningen, The Netherlands. ⁶⁰Maxima Medical Center, Veldhoven, The Netherlands. ⁶¹Gemini Hospital, Den Helder, The Netherlands. ⁶²Medical Center Leeuwarden, Leeuwarden, The Netherlands. ⁶³Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands. ⁶⁴Rode Kruis Hospital, Beverwijk, The Netherlands. ⁶⁵St. Antonius Hospital, Nieuwegein, The Netherlands. ⁶⁶Deventer Hospital, Deventer, The Netherlands. ⁶⁷Slingeland Hospital, Doetinchem, The Netherlands. ⁶⁸Refaja Hospital, Stadskanaal, The Netherlands. ⁶⁹Bethesda Hospital, Hoogeveen, The Netherlands. ⁷⁰University Medical Center Groningen, Beatrix Children's hospital, Groningen, The Netherlands. ⁷¹Haga Hospital – Juliana Children's Hospital, Den Haag, The Netherlands. ⁷²Isala Hospital, Zwolle, The Netherlands. ⁷³Bernhoven Hospital, Uden, The Netherlands. ⁷⁴VieCuri Medical Center, Venlo, The Netherlands. ⁷⁵Ziekenhuisgroep Twente, Almelo-Hengelo, The Netherlands. ⁷⁶Catharina Hospital, Eindhoven, The Netherlands. ⁷⁷Reinier de Graaf Gasthuis, Delft, The Netherlands. ⁷⁸ETZ Elisabeth, Tilburg, The Netherlands. ⁷⁹Scheper Hospital, Emmen, The Netherlands. ⁸⁰St. Jansdal Hospital, Hardewijk, The Netherlands. ⁸¹Laurentius Hospital, Roermond, The Netherlands. ⁸²Isala Diaconessenhuis, Meppel, The Netherlands. ⁸³Zuyderland Medical Center, Sittard-Geleen, The Netherlands. ⁸⁴Westfriesgasthuis, Hoorn, The Netherlands. ⁸⁵Medisch Spectrum Twente, Enschede, The Netherlands. ⁸⁶St. Franciscus Gasthuis, Rotterdam, The Netherlands. ⁸⁷Streekziekenhuis Koningin Beatrix, Winterswijk, The Netherlands. ⁸⁸Flevo Hospital, Almere, The Netherlands. ⁸⁹Zuwe Hofpoort Hospital, Woerden, The Netherlands. ⁹⁰Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. ⁹¹Service of Neonatology, Lausanne University Hospital, Lausanne, Switzerland. ⁹²Infectious Diseases Service, Lausanne University Hospital, Lausanne, Switzerland. ⁹³Department of Pediatrics, Children's Hospital Lucerne, Lucerne, Switzerland. ⁹⁴Pediatric Infectious Diseases Unit, Children's Hospital of Geneva, University Hospitals of Geneva, Geneva, Switzerland. ⁹⁵Infectious Diseases and Vaccinology, University of Basel Children's Hospital, Basel, Switzerland. ⁹⁶Children's Hospital Aarau, Aarau, Switzerland. ⁹⁷Division of Infectious Diseases and Hospital Epidemiology, Children's Hospital of Eastern Switzerland St. Gallen, St. Gallen, Switzerland. ⁹⁸Department of Neonatology, University Hospital Zurich, Zurich, Switzerland. ⁹⁹Division of Infectious Diseases and Hospital Epidemiology, and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland. ¹⁰⁰Children's Hospital Chur, Chur, Switzerland. ¹⁰¹Alder Hey Children's Hospital, Clinical Research Business Unit, Eaton Road, Liverpool, L12 2AP, United Kingdom. ¹⁰²Department of Pediatric and Adolescence Surgery, Division of General Pediatric Surgery, Medical University Graz, Graz, Austria. ¹⁰³Department of Pediatrics, General Hospital of Steyr, Steyr, Austria. ¹⁰⁴Department of Pediatrics/Department of Pediatric Surgery, Technische Universität München (TUM), Munich, Germany. ¹⁰⁵Department of Pediatrics, Kepler University Clinic, Medical Faculty of the Johannes Kepler University, Linz, Austria. ¹⁰⁶Department of Pediatrics and Adolescent Medicine LKH Villach, Villach, Austria. ¹⁰⁷Department of Pediatrics and Adolescent Medicine and Neonatology, Hospital Ludmillerstift, Meppen, Germany. ¹⁰⁸Hospital for Children's and Youth Medicine, Oberschwabenklinik, Ravensburg, Germany. ¹⁰⁹Department of Pediatrics, Medical University Innsbruck, Innsbruck, Austria. ¹¹⁰Clinic for Paediatrics and Adolescents Medicine, Sana Hanse-Klinikum Wismar, Wismar, Germany. ¹¹¹Department of Pediatrics, Medical Center Coburg, Coburg, Germany. ¹¹²University Medicine Rostock, Department of Pediatrics (UKJ), Rostock, Germany. ¹¹³Department of Pulmonology, Medical University Graz, Graz, Austria. ¹¹⁴Institute for Hygiene and Microbiology, University of Würzburg, Würzburg, Germany. ¹¹⁵Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, Graz, Austria. ¹¹⁶Department of Pediatric Orthopedics and Adult Foot and Ankle Surgery, Orthopedic Hospital Speising, Vienna, Austria. ¹¹⁷Department of Paediatrics, Regional Hospital Bolzano, Bolzano, Italy. ¹¹⁸Department of Pediatrics and Adolescent Medicine, General Hospital Hochsteiermark/Leoben, Leoben, Austria. ¹¹⁹Department of Neonatology and Paediatric Intensive Care, Children's University Hospital, RWTH Aachen, Aachen, Germany.

¹²⁰Paediatric Intensive Care Unit, Department of Paediatric Surgery, Donauspital Vienna, Vienna, Austria. ¹²¹Department of Pediatrics, General Public Hospital, Zwettl, Austria. ¹²²Pediatric Clinic Dortmund, Dortmund, Germany. ¹²³Department of Pediatrics and Adolescent Medicine, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria. ¹²⁴Catholic Children's Hospital Wilhelmstift, Department of Pediatrics, Hamburg, Germany. ¹²⁵Department of Pediatrics, Krankenhaus Dornbirn, Dornbirn, Austria. ¹²⁶Children's Hospital Luedenscheid, Maerkische Kliniken, Luedenscheid, Germany. ¹²⁷Department of General Paediatrics, Medical University Graz, Graz, Austria. ¹²⁸Department of Paediatrics, Schwarzwald-Baar-Hospital, Villingen-Schwenningen, Germany. ¹²⁹Department of Paediatrics and Adolescents Medicine, University Hospital Erlangen, Erlangen, Germany. ¹³⁰Department of Pediatrics and Adolescent Medicine, Medical University of Salzburg, Salzburg, Austria. ¹³¹Paediatric Intensive Care Unit, Medical University Graz, Graz, Austria. ¹³²Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universitaet, Munich, Germany. ¹³³Mother and Child Health Care Institute of Serbia, Belgrade, Serbia. ¹³⁴Department of Pediatric and Adolescence Surgery, Division of Pediatric Orthopedics, Medical University Graz, Graz, Austria. ¹³⁵Department of Pediatrics, Academic Teaching Hospital, Landeskrankenhaus Feldkirch, Feldkirch, Austria. ¹³⁶University Children's Hospital, University of Cologne, Cologne, Germany. ¹³⁷Department of Pediatrics and Adolescent Medicine Wilheminspital, Vienna, Austria. ¹³⁸Department of Pediatric Surgery, Municipal Hospital Karlsruhe, Karlsruhe, Germany. ¹³⁹Hospital of the Sisters of Mercy Ried, Department of Pediatrics and Adolescent Medicine, Ried, Austria. ¹⁴⁰Hospital St. Josef, Braunau, Austria. ¹⁴¹Christophorus Kliniken Coesfeld Clinic for Pediatrics, Coesfeld, Germany. ¹⁴²Department of Paediatrics, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems, Austria. ¹⁴³Children's Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania.